Search Results

Data Presented on Cook's REFORM Trial at ISET

January 19, 2010—Cook Medical (Bloomington, IN) announced that findings from the REFORM clinical trial were presented by Robert Bersin, MD, at the 22nd Annual International Symposium on Endovascular Therapy (ISET) in Hollywood, Florida.

Data Presented on Cook's REFORM Trial at ISET

January 19, 2010—Cook Medical (Bloomington, IN) announced that findings from the REFORM clinical trial were presented by Robert Bersin, MD, at the ISET 2010: International Symposium on Endovascular Therapy in Hollywood, Florida.

Cook Medical Applies for FDA Approval of Its Balloon-Expandable Renal Artery Stent

September 24, 2010—Cook Medical (Bloomington, IN) announced that the company has submitted its premarket approval application to the US Food and Drug Administration for its new balloon-expandable stent for renal artery disease.

Pathway Medical Technologies Introduces Jetstream G2 NXT

August 10, 2009—Pathway Medical Technologies, Inc. (Kirkland, WA) announced the market launch of the Jetstream G2 NXT, a 7-F–compatible version of its peripheral atherectomy catheter.

Pathway Medical Technologies Introduces Jetstream G2 NXT

August 10, 2009—Pathway Medical Technologies, Inc. (Kirkland, WA) announced the market launch of the Jetstream G2 NXT, a 7-F–compatible version of its peripheral atherectomy catheter.

Cook's REFORM Trial Completes Enrollment

June 15, 2009—Cook Medical (Bloomington, IN) announced the completion of patient enrollment in the REFORM clinical trial of its Formula balloon-expandable stent for treating renal artery stenosis.

FDA Approves Cook Medical's Formula Renal Stents, REFORM Data Presented at ISET

January 18, 2011—Cook Medical (Bloomington, IN) announced that it has received premarket approval from the US Food and Drug Administration for the Formula balloon-expandable renal stent system.

Cordis Incraft System Studied in INNOVATION

April 11, 2010—Cordis Corporation (Bridgewater, NJ) announced that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of the company's new Incraft stent graft system to treat abdominal aortic aneurysms (AAAs).

Cordis Commences INNOVATION Trial of Very Low-Profile Incraft System to Treat AAA

April 11, 2010—Cordis Corporation (Bridgewater, NJ) announced that the first patients have been enrolled in the INNOVATION trial, which will assess the safety of the company's new Incraft stent graft system to treat abdominal aortic aneurysms (AAA).